Vonoprazan pharmacokinetics and effects on gastric pH following administration to fed and fasted horses
Data files
Jan 07, 2026 version files 25.66 KB
-
Pharmacokinetic_Parameters.xlsx
12.70 KB
-
README.md
2.13 KB
-
Vonoprazan_pH_Assessments.xlsx
10.84 KB
Abstract
This dataset supports research characterizing the pharmacokinetics of vonoprazan and investigating its effects on gastric pH in horses. The data set includes pharmacokinetic parameters for individual horses generated using non-compartmental pharmacokinetic analysis and the commercially available software program Phoenix WinNonlin (Certara, Princeton, NJ). Pharmacokinetic parameters generated from the pilot study (2 horses/group), assessing the effects of food on drug behavior (0.5 and 1 mg/kg oral doses), and a “full” study (n=6 horses) assessing the effects of a 1 mg/kg oral dose administered with food are included. A second data set includes gastric pH measurements as part of the “full” study (n=6 horses), both before and after vonoprazan administration (1 mg/kg oral dose). Measurements were collected via an engineered probe that was used to continuously measure intragastric pH for 12 hours before and 24 hours after each treatment. Sandhill Scientific software (Milwaukee, WI, USA) was used to determine the mean, maximum, and minimum pH. Calculations of the %t>pH4 were calculated at different time intervals. While the number of horses studied was limited, the results of the current study provide data that will be helpful in the design of further studies to assess the efficacy of vonoprazan in horses for the treatment of gastric ulcers.
Dataset DOI: 10.5061/dryad.8w9ghx41m
Description of the data and file structure
The first data set lists individual animal pharmacokinetic parameters for both the pilot study (fed vs fasted) and the full study (0.5 and 1 mg/kg doses). Parameters were generated using non-compartmental analysis (NCA) and the software program Phoenix WinNonlin (Certara, Princeton, NJ).
The second data set lists % of the time that pH was above and below 4 for individual animals. Dose groups include 0.5 and 1 mg/kg, omeprazole (positive control), and water (negative control).
Files and variables
File: Pharmacokinetic_Parameters.xlsx
Description: Pharmacokinetic parameters for the pilot and full study as generated by Phoenix WinNonlin software and non-compartmental analysis (NCA)
Variables
- Horse
- Dose
- Lambdaz: terminal slope
- HL Lambda z: terminal half-life
- Tmax: time of maximum concentration
- Cmax: maximum measured concentration
- AUC inf: area under the curve extrapolated to infinity
- AUC% % extrap: percentage of the curve that is extrapolated
File: Vonoprazan_pH_Assessments.xlsx
Description: pH assessments (time above and below pH4 ) for the dose groups
Variables
- Pre-%pH above 4: time pH is above 4 before drug administration
- Pre-%pH below 4: time pH is below 4 before drug administration
- Post-%pH above 4: time pH is above 4 after drug administration
- Post-%pH below 4: time pH is below 4 after drug administration
Code/software
No software is needed to view data. Any program that will open a spreadsheet, such as Excel, is recommended.
For PK analysis, the Phoenix NLME software program (V8.3; Certara, Princeton, NJ) was used.
Sandhill Scientific software (Milwaukee, WI, USA) was used to determine the mean, maximum, and minimum pH, and calculations of the %t>pH4.
Access information
Other publicly accessible locations of the data:
- None
Data was derived from the following sources:
- None
The study was conducted as a randomised four‐way balanced crossover study. Six horses received vonoprazan (0.5 and 1 mg/kg), omeprazole (4 mg/kg), and water (60 mL). Blood samples were collected prior to and up to 72 h post‐administration. Plasma vonoprazan concentrations were measured using liquid chromatography–tandem mass spectrometry, and non‐compartmental and compartmental pharmacokinetic analyses were performed. Intragastric pH was continuously recorded 12 h before and 24 h after each treatment. The percentage of time pH remained above 4 was compared among treatments.
